Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously”In the company’s words, NCT04319757 on ClinicalTrials.gov
- Tested for
- Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer
- Main trialPhase 1
- “ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II starting dose for ACE1702.”In the company’s words, NCT04319757 on ClinicalTrials.gov
Other drugs for Locally Advanced Solid Tumor
- FutibatinibTaiho · Phase 2/3
- TinengotinibTransThera Sciences (Nanjing), Inc. · Phase 3
- CTX-009Compass Therapeutics · Phase 2/3
- NanvuranlatJ-Pharma Co., Ltd. · Phase 3
- IvosidenibServier Bio-Innovation LLC · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 15 Jul 2024 | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026